Akthelia has a novel antimicrobial strategy
Akthelia is focused on the discovery and development of novel antimicrobial therapeutics which enhance the body‘s innate microbial defence mechanisms.
Akthelia has developed a pipeline of small molecule drug candidates for targeting microbial infections. Proof-of-concept studies in animals as well as in the clinic have shown that these drug candidates are safe and effective in both gastrointestinal and lung infections.
An important aspect of our strategy is that, unlike traditional antibiotics, treatment using Akthelia’s actives is unlikely to result in resistance.